Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
There are many available treatments for pulmonary embolism (PE), but the best treatment for
this condition is not known. The HI-PEITHO study will compare two treatment options that are
both available on the market for the treatment of PE.
Patients will be randomized 1:1 to receive either blood thinners (anticoagulation) or blood
thinners (anticoagulation) in combination with a device called the EkoSonicTM Endovascular
device to dissolve blood clots. Patients will be followed for 12 months after randomization
and have assessments while in the hospital as well as at 7 days, 30 days, 6 months and 12
months after randomization. The study will try to find out if one of these treatments is
better than the other at reducing the risk of death and other serious problems.
Phase:
Phase 4
Details
Lead Sponsor:
Boston Scientific Corporation
Collaborators:
National PERT Consortium, Inc. University Medical Center Mainz